CTAS — Technical + Fundamental Analysis | LONG SETUPCintas CorporationBATS:CTASshortermtraderAnalysis powered by proprietary software for multi-timeframe technical scoring and integrated fundamental valuation. Entry: $209.90 **Stop Loss:** $193.70 (-7.7%) Take Profit: $243 (+15.8%) R/R: ~2.05 🔍 Company Overview & Recent Results Cintas (CTAS) reported Q4 FY2026 results on July 15, posting revenue of $2.91B (+8.9% YoY)** and **adjusted EPS of $1.29 (+18.3%), beating consensus estimates. For the full fiscal year, revenue reached $11.26B (+8.9%) with a record operating margin of 23.1%. The FY2027 guidance of $12.10B–$12.25B also exceeded Wall Street expectations, signaling sustained momentum across healthcare, education, and hospitality verticals. 🏦 Analyst Reactions (Post-Earnings) FirmRatingTargetUpside vs $209.9 Wells FargoOverweight$250+19.1% Goldman SachsBuy$231+10.1% UBSBuy$230+9.6% BofANeutral → Buy$230+9.6% Consensus (20 analysts)Buy$214.5+2.2% Recent 3-month consensus (8 analysts)Strong Buy$224.17+6.8% Wells Fargo raised its target to $250**, maintaining Overweight. Goldman Sachs lifted to **$231, citing strength in non-cyclical end-markets. BofA upgraded to Buy, highlighting +400bps margin expansion driven by tech innovations and synergies from the UniFirst acquisition. **GF Value™ estimate: $210.09** — essentially in line with the current price of ~$209.9, suggesting fair valuation. 📈 Technical Analysis (as of July 27, 2026 — Proprietary Scoring System) Timeframe,RSI,MACD,Trend,Signal Daily74.68.39 > 6.19BullishBUY 4H76.96.38 > 6.24BullishBUY 1H77.82.10 > 1.59BullishBUY All three timeframes are fully aligned on BUY, with MACD firmly positive across the board. RSI readings are strong but have not yet entered extreme overbought territory (>80), leaving room for further upside. Price is trading well above both the SMA-20 ($187.6) and SMA-50 ($178.8), confirming strong bullish momentum. ⚖️ Fundamental Assessment (Proprietary Score: 6/10) MetricAssessment Valuation (P/E 42.9, P/B 16.4, P/S 7.5)Overvalued → Sell Revenue Growth FY2026+8.9% → Weak Growth Net Income Growth FY2026Weak → Sell Debt/Equity 0.51, Interest Coverage infiniteBuy (Score 9/10) Operating Cash Flow$2.28B → Solid cash generation The stretched valuation multiples represent the primary risk. However, the projected EPS growth of +10.9% for FY2027, combined with margin expansion and strong free cash flow, supports the premium. 🎯 Trading Strategy Entry Zone: $209.90 (post-pullback support near intrinsic value) Stop Loss: $193.70 (below the daily SMA-20 and key technical support) Take Profit: $243 (in-line with Wells Fargo's bull case target; potential stretch to $250) Key Catalysts Ahead: UniFirst acquisition synergies estimated at $375M Ongoing margin expansion through technology and operational efficiencies Growth in adjacent verticals (First Aid, Fire Safety) ⚠️ Not financial advice. Always conduct your own due diligence before making investment decisions.